Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer th…
Sponsor: NRG Oncology
NCT ID: NCT04804644
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting NIH
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04166409
Sites in Virginia: - Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 3 Recruiting Industry
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05580562
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Children's Hospital of The King's Daughter — Norfolk, Virginia
Phase 2, Phase 3 Recruiting Academic/Other
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and …
Sponsor: Global Coalition for Adaptive Research
NCT ID: NCT03970447
Sites in Virginia: - University of Virginia Health — Charlottesville, Virginia
Phase 3 Recruiting Industry
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together…
Sponsor: NovoCure GmbH
NCT ID: NCT06556563
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in Virginia: - Johnston Willis Hospital — Richmond, Virginia
Phase 2 Recruiting Network
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to …
Sponsor: Children's Oncology Group
NCT ID: NCT04684368
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy alone (temozo…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05432804
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the secon…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT06810544
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
The objective of the study is to evaluate efficacy and safety of zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.
Sponsor: Exelixis
NCT ID: NCT07428616
Sites in Virginia: - Inova Center for Personalized Health — Fairfax, Virginia
Phase 2 Recruiting Academic/Other
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (a…
Sponsor: David Reardon, MD
NCT ID: NCT02977780
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Virginia: - Research Site — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor re…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05386108
Sites in Virginia: - Virginia Cancer Institute — Norfolk, Virginia
Phase 1, Phase 2 Recruiting Industry
This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's bes…
Sponsor: NaviFUS Corporation
NCT ID: NCT06329570
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 1 Recruiting Industry
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Sponsor: Iambic Therapeutics, Inc
NCT ID: NCT06253871
Sites in Virginia: - NEXT Oncology - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1 Recruiting Industry
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Sponsor: A2A Pharmaceuticals Inc.
NCT ID: NCT06136884
Sites in Virginia: - Next Oncology -Virginia — Fairfax, Virginia
NA Recruiting Academic/Other
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor pa…
Sponsor: Virginia Commonwealth University
NCT ID: NCT06989086
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia
NA Recruiting Academic/Other
The goal of this clinical trial is to learn about the acceptability and feasibility of Cognitive Strategies, Mindfulness, and Rehabilitation Therapy (C-SMART) and Brain health Education and Wellness (BE Well) in adults with brain tumors an…
Sponsor: Virginia Commonwealth University
NCT ID: NCT07224503
Sites in Virginia: - Virginia Commonwealth University — Richmond, Virginia